Search results
Results From The WOW.Com Content Network
Digoxin immune Fab used to treat digoxin toxicity The primary treatment of digoxin toxicity is digoxin immune fab , which is an antibody made up of anti-digoxin immunoglobulin fragments. This antidote has been shown to be highly effective in treating life-threatening signs of digoxin toxicity such as hyperkalemia, hemodynamic instability, and ...
Digoxin (better known as Digitalis), sold under the brand name Lanoxin among others, is a medication used to treat various heart conditions. [4] Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure. [4] Digoxin is one of the oldest medications used in the field of cardiology.
A case series of 147 patients showed that not all cases of acute digoxin overdose require anti‐digoxin Fab, nor should anti‐digoxin Fab dose be calculated based on ingested dose. In contrast, a higher mortality (7.6%) was noted in a case series of acute and chronic digoxin and digitoxin poisoning despite Fab being used first line.
Most chapters within a unit are organized as follows, although there are some exceptions. Nursing-sensitive patient outcomes (NOC) are discussed before interventions. This is because in the sequence of clinical reasoning desired outcomes are identified prior to selection of interventions to achieve the outcomes.
There is no evidence that digoxin reduces mortality in CHF, although some studies suggest a decreased rate in hospital admissions. [27] It is contraindicated in cardiac tamponade and restrictive cardiomyopathy. The inotropic agent dobutamine is advised only in the short-term use of acutely decompensated heart failure, and has no other uses. [13]
An unusual side effect of digoxin is a disturbance of color vision (mostly yellow and green) called xanthopsia. Vincent van Gogh's "Yellow Period" may have somehow been influenced by concurrent digitalis therapy. Other oculotoxic effects of digoxin include generalized blurry vision, as well as seeing a "halo" around each point of light.
Type A: augmented pharmacological effects, which are dose-dependent and predictable [5]; Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug (e.g., nausea from digoxin), and they are therefore predictable.
Drugs which may be started with an initial loading dose include digoxin, teicoplanin, voriconazole, procainamide and fulvestrant. One or series of doses that may be given at the onset of therapy with the aim of achieving the target concentration rapidly.